Veiga-Fernández A, Luque-Molina MS, Ferreres-García K, Mendizábal-Vicente EM, Rincón-Olbes P, Lizárraga-Bonelli S

Language: Spanish
References: 31
Page: 499-507
PDF size: 286.50 Kb.

ABSTRACT

Objective: To determine the prevalence of occult cancer in BRCA1 and/or BRCA2 patients undergoing prophylactic bilateral salpingo-oophorectomy. To determine associated clinical or epidemiological factors. To evaluate surgical complications in surgeries performed via laparoscopy.
Material and Methods: Retrospective observational study conducted at the Gregorio Marañón hospital between 2012 and 2018. Review of prophylactic bilateral salpingooophorectomies performed in patients with confirmed BRCA1 and/or 2 mutations and not previously diagnosed with ovarian and/or fallopian cancer. Main variables: family history, age, body mass index, smoking habit, genetic mutation, previous abdominal surgeries, breast cancer, surgery date, surgical time, type of surgery, technique of the entrance to the abdominal cavity, surgical complications. The statistical analysis was performed using SPSS 17.0.
Results: 59 patients were included. The prevalence of occult cancer was 5/59. The average age (at the time of surgery) of patients diagnosed with occult cancer was 47.8 years. 43/59 had a history of breast cancer; in this group occult cancer was found in two patients. In the group with no history of breast cancer, frequency of occult cancer was 3/16. No statistically significant differences were found between both groups (p = 0.118). All patients diagnosed with occult cancer, except one, were smokers. The rate of intraoperative complications was 2/51 and 1/51 postoperative.
Conclusions: Patients with BRCA1 and/or BRCA2 mutations are a group of high cancer risk that require specific monitoring and advice in specialized units of third level hospitals.

REFERENCES

1. Maki Y, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266: 66- 71. doi:10.1126/science.7545954

2. Wooster R, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378: 789-92. doi:10.1038/378789a0

3. Finch A, et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA. 2006; 296: 185- 92. doi: 10.1001/jama.296.2.185

4. Antoniou A, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Human Genet. 2003; 72: 1117- 30. doi: 10.1086/375033

5. Ford D, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998; 62: 676-89. doi: 10.1086/301749

6. Struewing JP, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997; 336: 1401-8. doi:10.1056/ NEJM199705153362001

7. Gayther SA, et al. Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat Genet 1997; 15: 103-5. doi: 10.1038/ ng0197-103

8. Burke W, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA. 1997; 277: 997-1003. doi:10.1001/ jama.1997.03540360065034

9. Jacobs IJ, et al. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet 1999; 353: 1207-10. doi: 10.1016/S0140-6736 (98) 10261-1

10. Van Nagell JR Jr, et al. The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynecol Oncol 2000; 77: 350-6. doi:10.1006/ gyno.2000.5816

11. Laframboise S, et al. Use of CA-125 and ultrasound in highrisk women. Int J Gynecol Cancer 2002; 12: 86-9. http:// dx.doi.org/10.1136/ijgc-00009577-200201000-00014

12. Rebbeck TR, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002; 346: 1616-22. doi: 10.1056/NEJMoa012158

13. Kauff ND, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002; 346: 1609-15. doi: 10.1056/NEJMoa020119

14. Finch A, et al. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gyn Oncol. 2006; 100: 58-64. doi:10.1016/j. ygyno.2005.06.065

15. Powell CB, et al. Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. J Clin Oncol. 2005; 23: 127-32. doi:10.1200/JCO.2005.04.109

16. Kauff ND, et al. Risk reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 of BRCA2. J Clin Oncol. 2007; 25:2921-2927. doi: 10.1200/ JCO.2007.11.3449

17. Kauff ND, et al. Multi-centre prospective analysis of risk reducing salpingoophorectomy to prevent BRCA-associated breast and ovarian cancer. J Clin Oncol. 2006; 24: 49S (suppl, abstr 1003). doi: 10.1200/JCO.2007.13.9626

18. Lu KH, et al. Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. J Clin Oncol. 2000; 18: 2728-32. doi:10.1200/ JCO.2000.18.14.2728

19. Carcangiu ML, et al. Incidental carcinomas in prophylactic specimens in BRCA1 and BRCA2 germ-line mutation carriers, with emphasis on fallopian tube lesions: report of 6 cases and review of the literature. Am J Surg Pathol. 2006; 30: 1222-30. doi:10.1097/01. pas.0000202161.80739.ac

20. Schneider C, et al. Primary carcinoma of the fallopian tube. A report of 19 cases with literature review. Eur J Gynaecol Oncol 2000; 21: 578-82. https://www.ncbi.nlm.nih.gov/ pubmed/11214613?dopt=Abstract

21. Olivier RI, et al. Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up. British Journal of Cancer 2004; 90: 1492-97. doi:10.1038/sj.bjc.6601692

22. Schubert EL, et al. BRCA2 in American families with four or more cases of breast or ovarian cancer: recurrent and novel mutations, variable expression, penetrance, and the possibility of families whose cancer is not attributable to BRCA1 or BRCA2. Am J Hum Genet 1997; 60: 1031-40. https:// www.ncbi.nlm.nih.gov/pmc/articles/PMC1712449/

23. Tong D, et al. BRCA1 gene mutations in sporadic ovarian carcinomas: detection by PCR and reverse allele-specific oligonucleotide hybridization. Clin Chem 1999; 45: 976- 81. http://clinchem.aaccjnls.org/content/45/7/976.long

24. Hartley A, et al. Clear cell carcinoma of the fimbria of the fallopian tube in a BRCA1 carrier undergoing prophylactic surgery. Clin Oncol (R Coll Radiol) 2000; 12: 58-59. doi: https://doi.org/10.1053/clon.2000.9113

25. Rose PG, et al. Germline BRCA2 mutation in a patient with fallopian tube carcinoma: a case report. Gynecol Oncol 2000; 77: 319-20. doi: 10.1006/gyno.2000.5740.

26. Sobol H, et al. Fallopian tube cancer as a feature of BRCA1- associated syndromes. Gynecol Oncol 2000; 78:263-64. doi: 10.1006/gyno.2000.5897.

27. Zweemer RP, et al. Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations. Gynecol Oncol 2000; 76: 45-50. doi: 10.1006/gyno.1999.5623.

28. Agoff SN, et al. Unexpected gynecologic neoplasms in patients with proven or suspected BRCA1 or -2 mutations: implications for gross examination, cytology, and clinical follow-up. Am J Surg Pathol 2002; 26:171-78. doi:10.1097/00000478-200202000-00003

29. Hirst JE, et al. High rates of occult fallopian tube cancer diagnosed at prophylactic bilateral salpingo-oophorectomy. Int J Gynecol Cancer 2009; 19: 826-29. doi10.1111/ IGC.0b013e3181a1b5dc

30. O’Boyle CJ, et al. Laparoscopic oophorectomy: description and report of an initial series. Br J Surg. 1996; 83: 986. https://doi.org/10.1002/bjs.1800830732

31. Willsher P, et al. Laparoscopic oophorectomy in the management of breast disease. ANZ J. Surg. 2008; 78: 670-72. doi:10.1111/j.1445-2197.2008.04614.x